Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Zhonghua Jie He He Hu Xi Za Zhi ; 46(7): 725-729, 2023 Jul 12.
Artículo en Zh | MEDLINE | ID: mdl-37402666

RESUMEN

Schizophrenic and pregnant smokers with tobacco dependence had always been excluded from most large treatment trials for nicotine dependence. As weight gain was found to be common after smoking cessation, obese people were more likely to have a reduced willingness to quit smoking and an increased risk of relapse. This article reviewed the latest research progress in pharmacological treatment of tobacco dependence in schizophrenia, pregnant women, and obese people.


Asunto(s)
Cese del Hábito de Fumar , Tabaquismo , Femenino , Humanos , Embarazo , Tabaquismo/tratamiento farmacológico , Fumar/efectos adversos , Obesidad
2.
Zhonghua Jie He He Hu Xi Za Zhi ; 45(10): 1050-1054, 2022 Oct 12.
Artículo en Zh | MEDLINE | ID: mdl-36207962

RESUMEN

Platelets-related pathophysiological mechanism and clinical research is one of the research hot topics in chronic obstructive pulmonary disease (COPD) at home and abroad. Increasing evidence has proved the association between thrombocytosis and COPD. Platelets activation interacts with COPD. Antiplatelet therapy has been shown to have significant effects on both short-term and long-term outcomes in COPD. Platelets inhibition may be an emerging therapeutic target for COPD, and antiplatelet therapy is expected to become an inexpensive and effective treatment for COPD. This article reviewed the research progress in platelets and COPD.


Asunto(s)
Plaquetas , Enfermedad Pulmonar Obstructiva Crónica , Humanos , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico
3.
J Gastroenterol ; 29(5): 631-6, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8000512

RESUMEN

Primary sclerosing cholangitis (PSC) frequently accompanies inflammatory bowel diseases. In an attempt to increase our understanding of the pathogenesis of PSC, we studied bile duct changes in rats with colitis which had been given N-formyl L-methionine L-leucine L-tyrosine (fMLT) rectally; fMLT is one of the chemotactic peptides produced by Escherichia coli, and is secreted into the bile by hepatocytes after it enters the portal blood. Transrectal administration of fMLT induced a marked inflammation in the portal triad and mild hepatocyte necrosis on the 4th day. The infiltrating leukocytes in the portal tract were mostly mononuclear cells, which densely infiltrated around the bile ducts. These mononuclear cells appeared to attach to bile duct epithelial cells, and they were more numerous in the smaller bile ducts. Electron microscopy revealed that lymphocytes were in direct contact with bile duct lining cells and that some epithelial cells had degenerated or collapsed. These results suggest that this E. coli-derived peptide may induce cholangitis in the small bile duct through cell-mediated mechanisms. Since these pathologic changes resemble those of the bile duct observed in the early stage of PSC, it can be concluded that bacterial chemotactic peptides may play a role in the pathogenesis of small-duct PSC.


Asunto(s)
Colangitis Esclerosante/inducido químicamente , N-Formilmetionina Leucil-Fenilalanina/análogos & derivados , Animales , Conductos Biliares Intrahepáticos/patología , Colangitis Esclerosante/patología , Colitis/complicaciones , Infecciones por Escherichia coli/complicaciones , Masculino , N-Formilmetionina Leucil-Fenilalanina/inmunología , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA